Skip to main content
SpringerLink
Log in

Worldwide Utilization of Implantable Cardioverter/Defibrillators Now and in the Future

  • Published:
Cardiac Electrophysiology Review

Abstract

Despite the demonstrated efficacy of implantable cardioverter defibrillators (ICDs) in reducing sudden and total mortality in selected patients, their implantation rates vary greatly between countries. In the United States, implantation rate is 228 implants per million inhabitants compared to only 45 implants per million in Western Europe. The differences in the ICD use may be explained by following factors: manner in which sudden cardiac death is perceived by politicians and physicians (sudden cardiac death is perceived as a “nice way of dying”); differences in indications; physicians' information; prevalence of coronary artery disease; sudden cardiac death survival rates; perceived reliability of alternative treatment (namely antiarrhythmics including amiodarone); economic backgrounds; and health care politics. Furthermore, the cost of this treatment strategy must be considered. This issue has been raised because generalization of ICD use in patients matching clinical characteristics of patients enrolled in the primary prevention trials may represent a significant economic burden to be added to the already overloaded health care system. This low acceptance may not be entirely related to budget constraint but also to the perceived efficacy of ICDs by physicians and health authorities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. AVID-Investigators (no authors listed). A comparison of antiarrhythmic drug therapy with implantable defibrillator in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus implantable defibrillators (AVID) investigators. N Engl J Med 1997; 337: 1576-1583.

    Google Scholar 

  2. Conolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitschell LB, Green MS, Klein GJ, O'Brien B. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297-1302.

    Google Scholar 

  3. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102(7): 748-754.

    Google Scholar 

  4. Moss AJ, Hall J, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AH, Wilber D, Brown MW, Heo M. Improved survival with an implantable defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med 1996; 33526): 1933-1940.

    Google Scholar 

  5. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.

    Google Scholar 

  6. Buxton AE, Lee Keton, Fisher JD, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N Engl J Med 1999; 341: 1882-1890.

    Google Scholar 

  7. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, Boczor S, Domanski M, Follmann D, Gent M, Roberts RS. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs. implantable defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21: 2071-2078.

    Google Scholar 

  8. Sheldon R, Connolly S, Krahn A, Roberts R, Gent M, Gardner M. Identification of patients most likely to benefit from implantable cardioverter defibrillator therapy: The Canadian Implantable Defibrillator Study. Circulation 2000; 101: 1660-1664.

    Google Scholar 

  9. Moss AJ. Implantable cardioverter defibrillator therapy: The sickest patients benefit the most. Circulation 2000; 101: 1638-1640.

    Google Scholar 

  10. Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, Kerber RE, Naccarelli GV, Schoenfeld MH, Silka MJ, Winters SL. ACC/AHA/NASPE 2002 Guidelines update for implantation of cardiac pacemakers and antiarrhythmia devices: Summary article. Circulation 2002; 106: 2145-2161.

    Google Scholar 

  11. Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TB Jr, Freedman RA, Hlatky MA, Naccarelli GV, Saksena S, Schlant RC, Slka MJ, Richie JL, Gibbons RJ, Cheitlin MD, Eagle KA, Gardner TJ, Lewis RP, O'Rourke RA, Ryan TJ, Garson A Jr. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). J Am Coll Cardiol 1998; 31(5): 1175-1209.

    Google Scholar 

  12. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, Camm AJ, Cappato R, Cobbe SM, Di Mario C, Maron BJ, McKenna WJ, Pedersen AK, Ravens U, Schwartz PJ, Trusz-glzua M, Vardas P, Wellens HJ, Zipes DP. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2001; 16: 1374-1450.

    Google Scholar 

  13. Seidl K, Senges J. Geographic differences in implantable cardioverter defibrillator usage. J Cardiovasc Electrophysiol 2002; 13(I Suppl): 100-105.

    Google Scholar 

  14. Myerberg RJ, Catellanos A. Cardiac arrest and sudden cardiac death. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine, 5th ed. New York: WB Saunders, 1997: pp 742-779.

    Google Scholar 

  15. Zheng ZJ, Croft JB, Giles WH, Mesah GA. Sudden cardiac death in the United States 1989 to 1998. Circulation 2001; 104: 2155-2163.

    Google Scholar 

  16. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998; 98: 2334-2351.

    Google Scholar 

  17. Wever EF, Hauer RN, Schrijvers G, van Capelle FJ, Tijssen JG, Crijns HJ, Algra A, Ramanna H, Bakker PF, Robles de Medina EO. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided tiered strategy in postinfarct sudden death survivors. A randomized study. Circulation 1996; 93: 489-496.

    Google Scholar 

  18. de Vreede-Swagemakers JJ, Gorgels AP, Weijenberg MP, Dubois-Arbouw WI, Golombeck B, van Ree JW, Knottnerus A, Wellens HJ. Risk indicators for out-of-hospital cardiac arrest in patients with coronary artery disease. J Clin Epidemiol 1999; 52: 601-607.

    Google Scholar 

  19. Myerburg RJ, Castellanos A. Cardiac arrest and sudden death. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders, 1997: 742-779.

    Google Scholar 

  20. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen MJ, Houben IG, Wellens HJ. Out-of-hospital cardiac arrest in the 1990 's: A population-based study in the Maastricht areaon incidence, characteristics and survival. J Am Coll Cardiol 1997; 30(Suppl 6): 1500-1505.

    Google Scholar 

  21. White RD, Asplin BR, Bugliosi TF, Hankins DG. High discharge survival rate after out-of-hospital ventricular fibrillation with rapid defibrillation by police and paramedics. Ann Emer Med 1996; 28: 480-485.

    Google Scholar 

  22. Smith SC Jr, Hamburg RS. Automated external defibrillators: Time for federal and state advocacy and broader utilization. Circulation 1998; 97(13): 1321-1324.

    Google Scholar 

  23. Cobb LA, Weaver WD, Fahrenbruch CE, Hallstrom AP, Copass MK. Community-based interventions for sudden cardiac death. Impact, limitations, and charges. Circulation 1992; 85 (Suppl): I98-102.

    Google Scholar 

  24. Valenzuela TD, Roe DJ, Nichol G, Clark Lues, Spaite DW, Hardmann RG. Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. N Engl J Med 2000; 343(17): 1206-1209.

    Google Scholar 

  25. Delacretaz E, Schlaepfer J, Metzger J, Fromer M, Kappenberger L. Evidence rather than costs must guide use of the implantable cardioverter defibrillator. Am J Coll Cardiol 2000; 86 (Suppl): 52K-57K.

    Google Scholar 

  26. Stevenson WG, Ridker PM. Should survivors of myocardial infarction with low ejection fraction be routinely reffered to arrhythmia specialists? JAMA 1996; 276: 481-485.

    Google Scholar 

  27. Clementy J. The ICD in France: Money problem of donkey syndrome? PACE 1998; 21: 1683-1685.

    Google Scholar 

  28. Copie X, Piot O, Said MA, Lavergne T, Ollitrault J, Guize L, Le Heuzey JY, for the Medtronic ICD System Investigators. Temporal and geographical trends in indications for implantation of cardiac defibrillators in Europe 1993-1998. PACE2000; 23: 979-984.

    Google Scholar 

  29. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl Med 1992: 327: 669-677.

    Google Scholar 

  30. SOLVD Investigators (no authors listed). Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD-Investigators. N Engl J Med 1991; 325: 293-302.

    Google Scholar 

  31. CIBIS-Investigators (no authors listed). The cardiac Insufficiency bisprolol study II (CIBIS-II): A randomized trial. Lancet 1999; 353: 9-13.

    Google Scholar 

  32. ISIS-2 Collaborative group (no authors listed). Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among. ISIS-2. ISIS-2 (Second international study of infarct survival). Lancet 1988; 2: 349-360.

    Google Scholar 

  33. Merit-HF Study group (no authors listed). Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-2007.

    Google Scholar 

  34. 4 S Investigators (no authors listed). Randomized trail of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383-1389.

    Google Scholar 

  35. Ruskin JN, Camm AJ, Zipes DP, Hallstrom AP, McGrory-Usset ME. Implantable cardioverter defibrillator utilization based on discharge diagnoses from Medicare and managed care patients. J Cardiovasc Electrophysiol 2002; 13: 38-43.

    Google Scholar 

  36. Klein Helmut, Auricchio A, Reek S, Geller C. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol 1999; 83: 91D-97D.

    Google Scholar 

  37. Goldman L, Gordon DG, Rifkind BM, Hulley SB, Detsky AS, Goodman DW, Kinosian B, Weinstein MC. Cost and health implications of cholesterol lowering. Circulation 1992; 85: 1960-1968.

    Google Scholar 

  38. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost effectiveness analysis in heart disease. Part II. Preventive therapies. Progr Cardiovasc Dis 1995; 37: 243-271.

    Google Scholar 

  39. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart disease, congestive heart failure, and arrhythmias

  40. Kupersmith J. Cost-effective strategies in cardiology. In: Hurst JW et al., eds. The Heart Arteries and Veins, 9th edn. New York: McGraw Hill, 1998: 2557-2578.

    Google Scholar 

  41. Kuppermann M, Luce BR, McGovern B, Podrid PJ, Bigger JT Jr, Ruskin JN. An analysis of the cost-effectiveness of the implantable defibrillator. Circulation 1990; 81(1): 91-100.

    Google Scholar 

  42. O'Brian BJ, Connolly SJ, Goeree R, Blackhouse G, Willan A, Yee R, Roberts RS, Gent M, for the CIDS Investigators: Cost-effectiveness of the implantable cardioverter defibrillator: Results from the Canadian Implantable Defibrillators Study (CIDS). Circulation 2001; 102: 1416-1421.

    Google Scholar 

  43. Sheldon R, O'Brien BJ, Blackhouse G, Goeree R, Mitschell B, Klein G, Roberts RS, Gent M, Connolly SJ. Effect of clinical risk stratification on costeffectiveness of the implantable cardioverter-defibrillator: The Canadian implantable defibrillator study. Circulation 2001; 104(14): 1622-1626.

    Google Scholar 

  44. Bigger JT. Expanding indications for implantable cardiac defibrillators. N Engl J Med 2002; 346: 931-933.

    Google Scholar 

  45. Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, Owens DK. Potential costeffectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med 2001; 135(10): 870-883.

    Google Scholar 

  46. Zipes DP. Implantable Cardioverter-Defibrillator. A Volkswagen or a Rolls Royce: How much will we pay to save a life? Circulation 2001; 103: 1372-1374.

    Google Scholar 

  47. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S, Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344(12): 873-880.

    Google Scholar 

  48. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Haves DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346(24): 1845-1853.

    Google Scholar 

  49. Exner DV, Klein GJ, Prystowsky EN. Primary prevention of sudden death with implantable defibrillator therapy in patients with cardiac disease. Can we afford to do it? (Can we afford not to?). Circulation 2001; 104(13): 1564-1570.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Electrophysiology, Herzzentrum Ludwigshafen, Ludwigshafen, Germany

    K. Seidl & J. Senges

Authors
  1. K. Seidl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Senges
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seidl, K., Senges, J. Worldwide Utilization of Implantable Cardioverter/Defibrillators Now and in the Future. Card Electrophysiol Rev 7, 5–13 (2003). https://doi.org/10.1023/A:1023603118860

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1023603118860

Search

Navigation